-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Benzinga·08/06/2026 23:08:32
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.